Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study
- PMID: 18466045
- DOI: 10.4088/jcp.v69n0617
Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study
Abstract
Objective: This double-blind study examined whether olanzapine augments the efficacy of dialectical behavior therapy (DBT) in reducing anger and hostility in borderline personality disorder patients.
Method: Twenty-four women with borderline personality disorder (DSM-IV criteria) and high levels of irritability and anger received 6 months of DBT. Subjects were randomly assigned to receive either low-dose olanzapine or placebo and were assessed with standardized measures in a double-blind manner. The study was conducted from September 2000 to December 2002.
Results: Intent-to-treat analyses indicated that both treatment conditions resulted in significant improvement in irritability, aggression, depression, and self-inflicted injury (p < .01 for each). Irritability and aggression scores tended (p < .10) to decrease more quickly for the olanzapine group than for the placebo group. Self-inflicted injury tended (p < .10) to decrease more for the placebo group than for the olanzapine group.
Conclusions: Olanzapine may promote more rapid reduction of irritability and aggression than placebo for highly irritable women with borderline personality disorder. Effect sizes were moderate to large, with the small sample size likely limiting the ability to detect significant results. Overall, there were large and consistent reductions in irritability, aggression, depression, and self-injury for both groups of subjects receiving DBT.
Similar articles
-
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.Am J Psychiatry. 2005 Jun;162(6):1221-4. doi: 10.1176/appi.ajp.162.6.1221. Am J Psychiatry. 2005. PMID: 15930077 Clinical Trial.
-
Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.J Clin Psychiatry. 2001 Nov;62(11):849-54. doi: 10.4088/jcp.v62n1103. J Clin Psychiatry. 2001. PMID: 11775043 Clinical Trial.
-
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.CNS Drugs. 2017 Sep;31(9):809-819. doi: 10.1007/s40263-017-0458-4. CNS Drugs. 2017. PMID: 28741044 Clinical Trial.
-
Use of dialectical behavior therapy in inpatient treatment of borderline personality disorder: a systematic review.Psychiatr Serv. 2012 Sep 1;63(9):881-8. doi: 10.1176/appi.ps.201100311. Psychiatr Serv. 2012. PMID: 22751905 Review.
-
Psychological therapies for people with borderline personality disorder.Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005652. doi: 10.1002/14651858.CD005652. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD005652. doi: 10.1002/14651858.CD005652.pub2 PMID: 16437534 Updated. Review.
Cited by
-
Treating nonsuicidal self-injury: a systematic review of psychological and pharmacological interventions.Can J Psychiatry. 2014 Nov;59(11):576-85. doi: 10.1177/070674371405901103. Can J Psychiatry. 2014. PMID: 25565473 Free PMC article. Review.
-
Pharmacological interventions for people with borderline personality disorder.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD012956. doi: 10.1002/14651858.CD012956.pub2. Cochrane Database Syst Rev. 2022. PMID: 36375174 Free PMC article. Review.
-
Dialectical behavior therapy for adolescents: theory, treatment adaptations, and empirical outcomes.Clin Child Fam Psychol Rev. 2013 Mar;16(1):59-80. doi: 10.1007/s10567-012-0126-7. Clin Child Fam Psychol Rev. 2013. PMID: 23224757 Review.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2018 Jan 15;48(1):64-153. Psychopharmacol Bull. 2018. PMID: 29382960 Free PMC article. Review. No abstract available.
-
Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology. 2022 Feb;47(3):664-672. doi: 10.1038/s41386-021-01163-7. Epub 2021 Aug 26. Neuropsychopharmacology. 2022. PMID: 34446830 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources